Altiratinib blocks Toxoplasma gondii and Plasmodium falciparum development by selectively targeting a spliceosome kinase.
Sci Transl Med. 2022 Aug 3;14(656):eabn3231. doi: 10.1126/scitranslmed.abn3231. Epub 2022 Aug 3.
Sci Transl Med. 2022.
PMID: 35921477